drugset / Trial / NCT00034944

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)

NCT00034944 ↗

Phase 3 Completed 495 enrolled Merck Sharp & Dohme LLC
Double-blindTreatment

Summary

A clinical study to determine the efficacy and safety of MK0869 in the treatment of depression.

Timeline

Start
2002-01-24
Primary completion
2003-12-17
Completion
2003-12-17

Outcome

Missed primary endpoint

paper No statistically significant differences from placebo on the HAM-D(17) were observed at week 8 for either dose of aprepitant in any of the trials PMID 16248986 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Aprepitant Other / unclassified 80 mg —
Subject Aprepitant Other / unclassified 160 mg —